# Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Study · id `cardio:ct-nct07157774` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07157774](<https://clinicaltrials.gov/study/NCT07157774>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07157774

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10450 participants.

## Technical summary

Registry record NCT07157774. Randomized; double masking; primary purpose treatment. Start 2025-09-02 (actual); primary completion 2031-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 10450 participants (planned count; ClinicalTrials.gov record NCT07157774, source copy `cardio:ctgov-nct07157774-2026-09-24`, retrieved 2026-10-31)
- Started: 2025-09-02 (actual) (ClinicalTrials.gov record NCT07157774, source copy `cardio:ctgov-nct07157774-2026-09-24`, retrieved 2026-10-31)
- Primary completion: 2031-03 (anticipated) (ClinicalTrials.gov record NCT07157774, source copy `cardio:ctgov-nct07157774-2026-09-24`, retrieved 2026-10-31)
- Completion: 2031-03 (anticipated) (ClinicalTrials.gov record NCT07157774, source copy `cardio:ctgov-nct07157774-2026-09-24`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Greece; Hungary; India; Italy; Japan; Mexico; Netherlands; Poland; Puerto Rico; Romania; Singapore; Slovakia; South Korea; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT07157774, source copy `cardio:ctgov-nct07157774-2026-09-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07157774-2026-09-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- Acronym: MOVE-Lp(a)
- Condition: Elevated Lp(a)
- Condition: Atherosclerotic Cardiovascular Disease (ASCVD)
- Intervention (Drug): Muvalaplin
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 08aa74430c2cfebc6bcafd64130a38b75cae52169a700d1cff259976c68c6bfd
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
